TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11444081

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Men with low energy-adjusted calcium intake
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Men who increased alcohol intake during the intervention
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Long-term regular aerobic physical activity
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lumbar BMD
Number of subjects: 140
Study: 9745397

Group type: EXPERIMENTAL
Intervention: Octreotide (100 or 250 micrograms, sc, every 8 h for 6 months)
Number of subjects: 107
Study: 7988854

Group type: EXPERIMENTAL
Intervention: GnRH agonist (3.6 mg goserelin depot injection on cycle day 22 followed by individualized HMG stimulation 14 days later)
Number of subjects: 62

Group type: COMPARATOR
Intervention: HMG stimulation starting on cycle day 3
Number of subjects: 62
Study: 2659475

Group type: EXPERIMENTAL
Intervention: Combination therapy with slow-release theophylline (2 x 350 mg) and salbutamol aerosol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salbutamol monotherapy (placebo capsules)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination therapy with slow-release theophylline and salbutamol aerosol
Number of subjects: 40
Study: 1148964

Group type: EXPERIMENTAL
Intervention: Cephaloridine (prophylactic antibacterial therapy)
Number of subjects: 266

Group type: COMPARATOR
Intervention: No cephaloridine (control group)
Number of subjects: 266
Study: 28524025

Group type: EXPERIMENTAL
Intervention: Esmolol (0.05 mg×kg‐1×h‐1, titrated to decrease heart rate by 20% or below 95 bpm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (isotonic saline at 3 mL/h for 24 hours)
Number of subjects: 60
Study: 25733127

Group type: EXPERIMENTAL
Intervention: Wet suction technique (WEST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional FNA technique (CFNAT)
Number of subjects: 0
Study: 23937598

Group type: EXPERIMENTAL
Intervention: Experimental condition (impaired control paradigm)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Free-drinking condition
Number of subjects: 39
Study: 21948965

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg three times daily for 20 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 19838080

Group type: EXPERIMENTAL
Intervention: Tdap and TIV co-administered
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Tdap and TIV sequential administration (TIV followed by Tdap)
Number of subjects: 1497
Study: 16759390

Group type: EXPERIMENTAL
Intervention: Lutein supplementation (10 mg/d for 12 weeks followed by 30 mg/d for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (24 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lutein supplementation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15568661

Group type: EXPERIMENTAL
Intervention: Single-dose morning omeprazole
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single-dose morning rabeprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single-dose morning famotidine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single-dose evening omeprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single-dose evening rabeprazole
Number of subjects: 53
Study: 10998014

Group type: EXPERIMENTAL
Intervention: Sensitization to indoor allergens with bronchial hyperresponsiveness (BHR)
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Low levels of specific IgE to indoor allergens with BHR
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Sensitization to outdoor allergens
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Subjects with specific IgE to inhalant allergens (asymptomatic)
Number of subjects: 1904
Study: 9489411

Group type: EXPERIMENTAL
Intervention: Treatment of chronic pulmonary tuberculosis with 4-6 antituberculous drugs for not less than one year after sputum culture conversion.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard therapy with 3 or 4 drugs for recently diagnosed pulmonary tuberculosis.
Number of subjects: 48
Study: 8454118

Group type: EXPERIMENTAL
Intervention: Time spent on health education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time spent on physical examination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discussion of treatment effects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time spent on history taking
Number of subjects: 100
Study: 3530303

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Digoxin + Placebo
Number of subjects: 10
Study: 31901231

Group type: EXPERIMENTAL
Intervention: SOFT block with bupivacaine 0.25%
Number of subjects: 107

Group type: COMPARATOR
Intervention: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg)
Number of subjects: 107
Study: 30395878

Group type: EXPERIMENTAL
Intervention: E‐Sil dressings
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional dressings (CD)
Number of subjects: 120
Study: 29183926

Group type: EXPERIMENTAL
Intervention: Enhanced management with 3 monthly follow-up
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual by the general practitioner
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parallel observational group (no cognitive decline)
Number of subjects: 100
Study: 25752882

Group type: EXPERIMENTAL
Intervention: 4 mg DEX
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 8 mg DEX
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prophylactic DEX (4 mg) vs. steroid naïve cohort
Number of subjects: 47
Study: 24460303

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Perioperative comprehensive supportive care interventions including health education, psychological support, stress management, coping strategies, and behavior training.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 21775756

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 14
Study: 19197729

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide with rituximab (FCR)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 139
Study: 17004982

Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose 200 mg (two doses on days 2 and 4)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral ferrous sulphate 200 mg twice daily for 6 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 44
Study: 14762881

Group type: EXPERIMENTAL
Intervention: Irradiation (60-66 Gy over 30-33 daily fractions)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Surgery (horizontal or vertical partial laryngectomy, various minor procedures)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Irradiation
Number of subjects: 488

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 488
Study: 15635849

Group type: EXPERIMENTAL
Intervention: Physical training (3 times per week for 2 months on a bicycle ergometer)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 38
Study: 9205634

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg effervescent calcium tablet, Sandocal 1000)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7960357

Group type: EXPERIMENTAL
Intervention: 1% 8-MOP bathing suit treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo bathing suit treatment
Number of subjects: 24
Study: 3446438

Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 300

Group type: COMPARATOR
Intervention: Brevicon
Number of subjects: 300
Study: 31634752

Group type: EXPERIMENTAL
Intervention: Resistance training (3 sessions of 50 minutes per week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balance and tone program (control condition)
Number of subjects: 0
Study: 29437941

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (40 mg.kg(‐1))
Number of subjects: 61

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 61
Study: 27686002

Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine in combination with allopurinol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Azathioprine monotherapy
Number of subjects: 46
Study: 25070123

Group type: EXPERIMENTAL
Intervention: Thermal therapy using an infrared thermal blanket at 50°C for 40 minutes in addition to drug treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38
Study: 22768642

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Skin conductance level (SCL)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Heart rate and SCL combined
Number of subjects: 108
Study: 20558906

Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia (O2: 14.4%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 9
Study: 18485668

Group type: EXPERIMENTAL
Intervention: Grape antioxidant dietary fiber (7.5 g/d)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Grape antioxidant dietary fiber (7.5 g/d) in hypercholesterolemic subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (non-supplemented non-smokers)
Number of subjects: 34
Study: 16164654

Group type: EXPERIMENTAL
Intervention: Two-phase patient-centered educational intervention (educational booklets, 15-minute video, 90-minute small group session) in addition to regular multidisciplinary care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ongoing standard care and education in the multidisciplinary predialysis clinic
Number of subjects: 70
Study: 11476456

Group type: EXPERIMENTAL
Intervention: Fexofenadine 15 mg twice daily
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Fexofenadine 30 mg twice daily
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study: 9595871

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg taken 5 hours before the endogenous nocturnal plasma melatonin concentration reached 10 pg/mL
Number of subjects: 30
Study: 7802194

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 50 u.ml‐1 added to local anaesthetic mixture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standardised local anaesthetic mixture without hyaluronidase (Control)
Number of subjects: 60
Study: 15235828

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (20 mg administered one hour before surgery)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine (20 mg administered one hour before surgery)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Oral famotidine (20 mg administered the night before and on the morning of surgery)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (placebo, no famotidine)
Number of subjects: 128
Study: 31550073

Group type: EXPERIMENTAL
Intervention: MM-BK model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QSS model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MM-IDR model
Number of subjects: 0
Study: 30452208

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (mailed materials and telephone support)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 561
Study: 29122253

Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Silence (headphones without sound)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (routine care only)
Number of subjects: 93
Study: 23244443

Group type: EXPERIMENTAL
Intervention: Evidence-based strategies for recruitment (changing inclusion criteria, increasing study staff, branding the study, respectful engagement, pacing the process)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivators for participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment expenditures
Number of subjects: 0
Study: 21332976

Group type: EXPERIMENTAL
Intervention: AMC/DCBA Warm lozenge
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: AMC/DCBA Cool lozenge
Number of subjects: 225

Group type: COMPARATOR
Intervention: Unflavoured, non‐medicated lozenge
Number of subjects: 225
Study: 19820024

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16731209

Group type: EXPERIMENTAL
Intervention: Home-based speed-of-processing training (8 to 10 sessions of 1 hour each)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 181
Study: 15599677

Group type: EXPERIMENTAL
Intervention: hs-CRP levels measured at baseline and follow-up after 6 months
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: hs-CRP levels in patients without cardiac events
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: hs-CRP levels in patients with cardiac events
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: hs-CRP levels above 60% of initial level
Number of subjects: 133
Study: 11310517

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9636952

Group type: EXPERIMENTAL
Intervention: Lean tissue mass
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gymnasts (subgroup)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Swimmers (subgroup)
Number of subjects: 41
Study: 7930249

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (Group I)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (Group II)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No significant coronary artery disease
Number of subjects: 61
Study: 2765272

Group type: EXPERIMENTAL
Intervention: Low-fat high polyunsaturated fatty acids/saturated fatty acid ratio diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased intake of saturated fats
Number of subjects: 0
Study: 30802929

Group type: EXPERIMENTAL
Intervention: Homotopic heat stimuli at 45 °C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Homotopic heat stimuli at 50 °C
Number of subjects: 18

Group type: COMPARATOR
Intervention: Heterotopic counterstimuli
Number of subjects: 18
Study: 27888416

Group type: EXPERIMENTAL
Intervention: GSK239512
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 25384069

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study: 23759474

Group type: EXPERIMENTAL
Intervention: Coping Screen (4-item tool)
Number of subjects: 6210

Group type: EXPERIMENTAL
Intervention: PHQ-2 and GAD-2
Number of subjects: 6210

Group type: EXPERIMENTAL
Intervention: Panic item
Number of subjects: 6210
Study: 21683485

Group type: EXPERIMENTAL
Intervention: Specially formulated medical food (40 g protein, enriched with 10% free leucine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional medical food (24 g casein protein)
Number of subjects: 25
Study: 19921981

Group type: EXPERIMENTAL
Intervention: Cranberry juice 50 ml daily (n=28)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG drink 100 ml on 5 days a month (n=27)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 84
Study: 23850844

Group type: EXPERIMENTAL
Intervention: Remote ischaemic postconditioning (RIP)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Remote ischaemic postconditioning (RIP) in diabetic patients
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 15855510

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous infusion over 30 min t.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: 250 mg loading dose followed by 1,500 mg continuous infusion over 24 h
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1,000 mg intravenous infusion over 30 min t.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: 500 mg loading dose followed by 3,000 mg continuous infusion over 24 h
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose therapy as continuous infusion
Number of subjects: 16
Study: 12791417

Group type: EXPERIMENTAL
Intervention: NN2211 (GLP-1 derivative), dose levels: eight, administered before glucose dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10445896

Group type: EXPERIMENTAL
Intervention: Case management and community service reimbursement
Number of subjects: 5209

Group type: EXPERIMENTAL
Intervention: Caregiver training and support group participation
Number of subjects: 5209

Group type: COMPARATOR
Intervention: Medicare waiver reimbursement
Number of subjects: 5209
Study: 7875920

Group type: EXPERIMENTAL
Intervention: Waking analgesia followed by hypnotic analgesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waking analgesia followed by waking analgesia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia followed by waking analgesia
Number of subjects: 36
Study: 2704510

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanic acid
Number of subjects: 152

Group type: COMPARATOR
Intervention: clindamycin-gentamicin
Number of subjects: 152
Study: 338081

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30687908

Group type: EXPERIMENTAL
Intervention: Non-ablative vaginal erbium:YAG laser (VEL) treatment (20 min/session, thrice)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anticholinergic agent (4 mg fesoterodine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: β3-adrenoceptor agonist (25 mg mirabegron)
Number of subjects: 50
Study: 27866504

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal OXT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26223696

Group type: EXPERIMENTAL
Intervention: Telephone Support Services (TSS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 300
Study: 23650301

Group type: EXPERIMENTAL
Intervention: Antihypotensive therapy
Number of subjects: 367

Group type: COMPARATOR
Intervention: No antihypotensive therapy
Number of subjects: 367
Study: 21529354

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Visthesia
Number of subjects: 77
Study: 19149837

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) - continuous 17-beta estradiol patch at 36 microg/day plus cyclic oral medroxyprogesterone acetate 2.5 mg/day for 12 days/month
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 17017752

Group type: EXPERIMENTAL
Intervention: Ayurvedic intervention (exercise, Ayurvedic diet, meditation instruction, Ayurvedic herb supplement MA 471)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard diabetes education classes with primary care clinician follow‐up (Control)
Number of subjects: 60
Study: 12834197

Group type: EXPERIMENTAL
Intervention: CC atrophy in CDR 1 & 2 patients
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy in CDR 0.5 patients
Number of subjects: 170

Group type: COMPARATOR
Intervention: Frontal executive dysfunction associated with CC atrophy
Number of subjects: 170

Group type: COMPARATOR
Intervention: CC atrophy and WMH correlation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Combined effect of CC atrophy and WMH in verbal fluency test
Number of subjects: 170
Study: 10873882

Group type: EXPERIMENTAL
Intervention: Acetate dialysis with cuprammonium membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polysulfone membrane with acetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetate dialysis with polysulfone membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis with cuprammonium membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis with polysulfone membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 9315426

Group type: EXPERIMENTAL
Intervention: Various HIV-related medications
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Open-label design
Number of subjects: 71

Group type: COMPARATOR
Intervention: Trials published in journals of wide readership
Number of subjects: 71
Study: 1535110

Group type: EXPERIMENTAL
Intervention: Various treatments for myocardial infarction (exact treatments not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Review articles and textbook recommendations (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatments with no effect on mortality or potentially harmful treatments (control group)
Number of subjects: 0
Study: 4077377

Group type: EXPERIMENTAL
Intervention: Collagen protein (1.3 g/kg desirable body weight per day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soy protein (1.3 g/kg desirable body weight per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (very-low-calorie diet without specifying protein source)
Number of subjects: 8
Study: 29931143

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.05 mg/kg for 2 years
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Pl) for 2 years
Number of subjects: 80
Study: 28937025

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 62

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 62